* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Active or Prior GB Virus C Infection Does Not Protect against Vertical
Survey
Document related concepts
Marburg virus disease wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
West Nile fever wikipedia , lookup
Oesophagostomum wikipedia , lookup
Neonatal infection wikipedia , lookup
Henipavirus wikipedia , lookup
Antiviral drug wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
Hepatitis C wikipedia , lookup
Hepatitis B wikipedia , lookup
Diagnosis of HIV/AIDS wikipedia , lookup
Epidemiology of HIV/AIDS wikipedia , lookup
Microbicides for sexually transmitted diseases wikipedia , lookup
Transcript
BRIEF REPORT Active or Prior GB Virus C Infection Does Not Protect against Vertical Transmission of HIV in Coinfected Women from Tanzania Amy C. Weintrob,1 John D. Hamilton,1,2 Christine Hahn,1 Donna Klinzman,3 Gustav Moyo,4 Dietmar Zdunek,5 Georg Hess,6 Daniel K. Benjamin, Jr.,1 and Jack T. Stapleton3 Duke University Medical Center and 2Research Service, Veterans Affairs Medical Center, Durham, North Carolina; 3University of Iowa and Iowa Veterans Affairs Medical Center, Iowa City, Iowa; 4Tanzania Ministry of Health, Dares-Salaam, Tanzania; and 5Roche Laboratories, Penzberg, and 6Roche Diagnostics, Mannheim, Germany 1 To determine whether GB virus C (GBV-C) infection is associated with protection against vertical transmission of human immunodeficiency virus (HIV), we tested 186 HIVpositive pregnant women for GBV-C. Neither active nor prior GBV-C infection was associated with a lower rate of HIV acquisition among infants. Thus, GBV-C does not appear to protect against perinatal HIV acquisition. GB virus C (GBV-C) is a flavivirus that is closely related to hepatitis C virus; however, it does not replicate in hepatocytes and has not been associated with any specific disease (reviewed in [1]). GBV-C viremia can persist for decades without apparent illness, or the virus may be cleared with the formation of antibodies to envelope glycoprotein E2 [2, 3]. Recent studies found that coinfection with GBV-C in HIV-infected patients was associated with an increase in the duration of survival, independent of HIV treatment received, baseline CD4+ T lymphocyte count, age, sex, race, and mode of transmission (reviewed in [4]). GBV-C viremia was also shown to slow the Received 2 September 2003; accepted 16 November 2003; electronically published 1 March 2004. Financial support: Veterans Administration (merit review to J.T.S.), National Institutes of Health (grants AI 50478, AI 058740, and AI 27661 to J.T.S.), and National Institute of Child Health and Human Development (grant R03HD42940-01 to D.K.B.). Conflict of interest: G.H. and D.Z. are employees of Roche Diagnostics and Roche Laboratories, respectively, and produce the E2 antibody ELISA method used in this study. Presented in part: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 14–17 September 2003 (abstract H1722). Reprints or correspondence: Dr. Amy Weintrob, Duke University Medical Center, Box 3824, Durham, NC 27710 ([email protected]). Clinical Infectious Diseases 2004; 38:e46–8 2004 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2004/3806-00E2$15.00 e46 • CID 2004:38 (15 March) • BRIEF REPORT progression to AIDS in patients with coinfection. GBV-C replicates in CD4+ T lymphocytes in vitro [5], and coinfection of PBMCs with GBV-C and HIV has resulted in decreased HIV replication [6]. Although the mechanism of interaction between GBV-C and HIV is not completely understood, there is some evidence that GBV-C replication alters chemokine expression, which may contribute to the inhibition of HIV replication [7]. The prevalence of GBV-C viremia among blood donors is 1%–2% in the United States and up to 4% in some developed countries [1]. Among HIV-infected individuals, the prevalence of GBV-C viremia may be as high as 40% [8]. Parenteral transmission of GBV-C is well recognized, and recent studies suggest that sexual transmission occurs frequently as well [9]. Several studies have found a high rate of vertical transmission of GBVC (60%–80%) from viremic mothers [10, 11], and small studies have evaluated whether coinfection with HIV affects the vertical transmission of GBV-C. In one of these studies [10], 34 mothers with detectable GBV-C RNA levels were evaluated. Eight of these women were HIV positive. There was not a statistically significant difference in the rate of vertical transmission of GBV-C between babies who were born to mothers with HIV coinfection (50%) and those who were born to mothers without HIV infection (65%). Another study evaluated vertical transmission of GBV-C in HIV/GBV-C–coinfected women and found a rate of vertical transmission of GBV-C of 45%, which is similar to the rate seen in women without HIV infection [11]. The effect of maternal GBV-C viremia on the vertical transmission of HIV, however, remains unknown. Thus, we evaluated the effects of GBV-C infection on the vertical transmission of HIV using archived plasma samples obtained from HIV-positive women in Dar-es-Salaam, Tanzania, from 1992 through 1993. Methods. This was a retrospective cohort study using archived serum samples obtained for a study on the vertical transmission of HIV during the period of 1992–1993. The institutional review boards at Duke University (Durham, NC) and the University of Iowa (Iowa City, IA) approved the study. Women attending an antenatal clinic in Dar-es-Salaam, Tanzania, were addressed by a Swahili-speaking nurse and invited to participate in screening for the HIV vertical transmission study. Consenting women were interviewed privately to reconfirm their consent to having an HIV test performed, and they subsequently were tested for HIV by ELISA. Blood samples were stored at ⫺20C. Women who tested positive for HIV infection twice by ELISA were enrolled if they consented to continue with the study. Blood samples were obtained from their infants at birth and 6 weeks, 3 months, 6 months, 9 months, 12 months, 15 months, and 18 months after birth for determination of HIV RNA levels by RT-PCR. None of the study subjects received antiretroviral therapy. All serum samples were identified by a unique code, and laboratory personnel were blinded to clinical data. RNA was extracted from 200 mL of serum using a previously described guanidinium-isothiocyanate extraction method [6]. Onefourth of this RNA preparation was used in nested RT-PCR reactions to amplify GBV-C RNA using primers from the E2 coding region of the genome. Specifically, primers were as follows: outer sense, 5-GDC GYG AYT CGA ARA TMG AYG-3 (nt 1484–1505); outer antisense, 5-AAG ATC AAC GGG ACC AGC CGT GCC TCA-3 (nt 2229–2251); inner sense, 5-GAT ATC GAA RAT MGA YGT GTG GAG-3 (nt 1490–1512); inner antisense, 5-TTA GGT ACC GCC TCA GCC AGC TTC AT3 (nt 2219–2235) (sequence numbering based on the fulllength Iowa GBV-C isolate; GenBank accession no. AF121950 [5]). Reaction conditions and the protocol for PCR product identification were described elsewhere [6]. Negative and positive controls were included with each sample undergoing PCR testing. The presence of antibodies to GBV-C envelope glycoprotein E2 was determined by ELISA [12], using the mPlate anti-HGenv test (Roche Diagnostics). Statistical analyses were completed using Stata software, version 6.0/7.0 (Stata). Binomial 95% CIs were calculated using exact methods, when appropriate. P values are 2-tailed and were estimated using the Wilcoxon rank sum test. Results. Two thousand three hundred twenty-nine women were screened, and 320 (13.8%) were found to have antibodies to HIV. Of these women, 215 HIV-positive women enrolled in the study and had 131 live births. Of the 215 HIV-infected women enrolled in the vertical transmission study in Tanzania, 186 had serum samples available for GBV-C testing. All but 1 of the infants in this study were delivered vaginally. Ninetyeight (53%) of the 186 women had evidence of past or active GBV-C infection. Forty-four women (24%; 95% CI, 18%–30%) had detectable GBV-C RNA, and 54 (29%; 95% CI, 24%–37%) had anti-E2 antibodies. Two patients had both GBV-RNA and anti-E2 antibodies. The rate of vertical transmission of HIV according to GBVC status is shown in figure 1. HIV-positive women with GBVC viremia transmitted HIV to 25 (28%; 95% CI, 12%–49%) of their infants, compared with 26 (23%; 95% CI, 9%–44%) of the infants from women with anti-E2 antibody and 77 (26%; 95% CI, 17%–37%) of the infants from women without active or past GBV-C infection. There was no statistically significant difference in the rates of vertical transmission of HIV. Discussion. GBV-C viremia has been shown to be associated with an increase in the duration of survival among HIVinfected individuals, independent of HIV treatment, baseline CD4+ T lymphocyte count, age, sex, race, and mode of transmission (reviewed in [4]). Although the interactions between GBV-C and HIV are incompletely understood, there is evidence that GBV-C replication inhibits HIV replication [6, 7]. We studied the prevalence of GBV-C infection and the effects of coinfection with GBV-C on the vertical transmission of HIV in Tanzanian women who did not have access to antiretroviral therapy. The prevalence of GBV-C viremia in HIV-infected, pregnant Tanzanian women was 24%, and an additional 30% had detectable antibodies to envelope protein E2, indicating past GBV-C infection and clearance. Similar to previous studies [8], the prevalence of GBV-C viremia in HIV-infected women Figure 1. Rate of vertical transmission of HIV, according to the hepatitis GB virus C (GBV-C) status of the mother. P p .60 , for women with GBVC viremia versus those without GBV-C infection. P 1 .99 , for women with GBV-C antibodies versus those without GBV-C infection. +, Positive; ⫺, negative. BRIEF REPORT • CID 2004:38 (15 March) • e47 was significantly greater than the prevalence of GBV-C reported in the general population. However, the prevalence of GBV-C viremia in this study was lower than that seen in some HIV-infected cohorts. For example, a study of 362 HIVinfected individuals from the midwestern United States found a prevalence of GBV-C viremia of 40%, regardless of risk factors for HIV infection [6], and a retrospective evaluation of samples obtained from 271 HIV-infected individuals in the Multicenter AIDS Cohort Study (MACS) found a prevalence of GBV-C viremia of 39% [12]. We assume that the vast majority of HIV infections in Tanzania were transmitted sexually. GBV-C has been shown to be transmitted sexually as well as parenterally [10, 11]; therefore, this probably does not account for the difference in prevalence. All of the samples in this study were obtained in the same manner and frozen until use, so there should not have been technical difficulty in detecting GBV-C RNA in the samples. The lower overall rate of viremia and E2 antibody positivity may reflect an increased rate of clearance of GBV-C RNA without development of E2 antibody in HIV-positive individuals. In the MACS cohort, for example, 12 of 61 participants who were GBV-C RNA positive within 18 months of HIV seroconversion cleared their GBV-C viremia during 4–5 years of followup. Seventy-five percent of these patients did not develop E2 antibody, and these patients were 5.87 times more likely to die than were those who were persistently viremic [12]. Another factor that may contribute to the difference in the prevalence of GBV-C viremia seen in this cohort is that, presumably, the Tanzanian women had non–clade B HIV and either GBV-C genotype 1 or 5. It is unknown how either HIV or GBV-C diversity might affect the detection of GBV-C infection or the interaction between GBV-C and HIV. Thus, this study may not be applicable to all HIV-positive pregnant women. Previous studies found a high rate (45%–80%) of vertical transmission of GBV-C, but none of these studies evaluated the effects of coinfection with GBV-C on the vertical transmission of HIV. In this cohort, neither maternal GBV-C viremia nor E2 antibody was associated with a high level of protection against vertical HIV transmission. However, because of the relatively small number of subjects with an adequate volume of serum available for evaluation of GBV-C RNA or anti-E2 antibodies, this study did not have sufficient power to detect small differences in HIV transmission rates. With 51 coinfected women and 77 women with HIV infection alone, as well as a baseline rate of vertical transmission rate of 26%, then (with an a of 5% and using Fisher’s exact methods, given the small e48 • CID 2004:38 (15 March) • BRIEF REPORT sample size) the study had 80% power to detect an absolute difference of 20%. Nevertheless, these data do not support a protective effect of GBV-C infection on vertical transmission of HIV in Tanzanian women. The possible effect of vertical transmission of both HIV and GBV-C on long-term infant survival is currently under study. Acknowledgments We would like to thank the women in Tanzania who consented to the study and Stephanie O’Conner for assistance with the GBV-C testing logistics. References 1. Alter HJ. G-pers creepers, where’d you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 1997; 37:569–72. 2. Thomas DL, Vlahov D, Alter HJ, et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 1998; 177:539–42. 3. Tacke M, Schmolke S, Schlueter V, et al. Humoral immune response to the E2 protein of hepatitis G virus is associated with long-term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors. Hepatology 1997; 26: 1626–33. 4. Stapleton JT. GB virus type C/hepatitis G virus. Semin Liver Dis 2003; 23:137–48. 5. Xiang J, Wuenschmann S, Schmidt WN, Shao J, Stapleton JT. Fulllength GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol 2000; 74:9125–33. 6. Xiang J, Wuenschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707–14. 7. Xiang J, George SL, Wuenschmann S, et al. GBV-C infection inhibits CCR5 and CXCR4 HIV strains and alters chemokine and cytokine gene expression in PBMC cultures [abstract 156]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:114. 8. Rey D, Vidinic-Moularde J, Meyer P, et al. High prevalence of GB virus C/hepatitis G virus RNA and antibodies in patients infected with HIV type 1. Eur J Clin Microbiol Infect Dis 2000; 19:721–4. 9. Frey SE, Homan SM, Sokol-Anderson M, et al. Evidence for probable sexual transmission of the hepatitis G virus. Clin Infect Dis 2002; 34: 1033–8. 10. Zanetti A, Tanzi E, Romano L, et al. Multicenter trial on mother-toinfant transmission of GBV-C virus. J Med Virol 1998; 54:107–12. 11. Palomba E, Bairo A, Tovo PA. High rate of maternal-infant transmission of hepatitis G virus in HIV and hepatitis C virus–infected women. Acta Paediatrica 1999; 88:1392–5. 12. Williams C, Klinzman D, Yamashita T, et al. Persistent GBV-C type C infection is associated with decreased risk of death in HIV-seroconvertors in the Multicenter AIDS Cohort Study [abstract 159lb]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:116.